Article Text

Download PDFPDF

Correction: An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature

Statistics from Altmetric.com

Avenell A, Stewart F, Grey A, et al. An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. BMJ Open 2019;9:e031909. doi: 10.1136/bmjopen-2019-031909

This article has been corrected since it was first published online. Details of retractions and correspondence relating to some references were inadvertently omitted in the first version; the following references have since been corrected to:

[6]Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1 alpha-hydroxyvitamin D3 and calcium supplementation. Stroke 1997;28:736–9. [Retraction in Sato Y, Maruoka H, Oizumi K, et al. Stroke 2019 in press. DOI: 10.1161/01.STR.28.4.736].

[7]Sato Y, Honda Y, Kuno H, et al. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone 1998;23:291–6. [Retraction in: Sato Y, Honda Y, Kuno H, et al. Bone 2019;124:167].

[8]Sato Y, Manabe S, Kuno H, et al. Amelioration of osteopenia and hypovitaminosis D by 1alpha- hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:64–8. [Retraction in Sato Y, Manabe S, Kuno H, et al. J Neurol Neurosurg Psychiatry 2018;89:E5].

[9]Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone 2002;31:114–8. [Retraction in: Sato Y, Honda Y, Kaji M, et al. Bone 2018;106:212].

[10]Sato Y, Kanoko T, Satoh K, et al. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone 2005;36:61–8. [Retraction in: Sato Y, Kanoko T, Satoh K, et al. Bone 2018;106:213].

[11]Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811–6. [Retraction in Sato Y, Iwamoto J, Kanoko T, et al. Neurology 2016;87:239].

[12]Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005;165:1743–8. [Retraction in: Sato Y, Iwamoto J, Kanoko T, et al. JAMA Intern Med 2016;176:1256].

[13]Sato Y, Kanoko T, Satoh K, et al. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005;165:1737–42. [Retraction in: Sato Y, Kanoko T, Satoh K, et al. JAMA Intern Med 2016;176:1256].

[14]Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005;293:1082–8. [Retraction in: Sato Y, Honda Y, Iwamoto J, et al. JAMA 2016;315:2405].

[15]Sato Y, Iwamoto J, Kanoko T, et al. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924–9. [Retraction in: Sato Y, Iwamoto J, Kanoko T, et al. Mov Disord;31:1077].

[16]Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911–5. [Retraction in: Sato Y, Honda Y, Iwamoto J. Neurology 2016;87:239].

[17]Sato Y, Iwamoto J, Honda Y. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2011;82:1390-3. [Retraction in: Sato Y, Iwamoto, Honda Y. J Neurol Neurosurg Psychiatry 2018;89:E4].

[85]Clarke CE. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:510–11; author reply 511.

[86]Poole KE, Warburton EA, Reeve J. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;65:1513–14; author reply 1513–4.

[87]Caffrey N, Casey M, Walsh B. Substandard studies or substandard “standard-of-care.” J Bone Miner Res 2006; 21:491; author reply 492.

[88]Halbekath JM, Schenk S, von Maxen A, et al. Risedronate for the prevention of hip fractures: concern about validity of trials. Arch Intern Med 2007;167:513–14; author reply 514–515.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles